The Cigna Group

NYSE:CI Stock Report

Market Cap: US$73.9b

Cigna Group Future Growth

Future criteria checks 3/6

Cigna Group is forecast to grow earnings and revenue by 24.2% and 5.6% per annum respectively. EPS is expected to grow by 29.2% per annum. Return on equity is forecast to be 19.3% in 3 years.

Key information

24.2%

Earnings growth rate

29.2%

EPS growth rate

Healthcare earnings growth20.8%
Revenue growth rate5.6%
Future return on equity19.3%
Analyst coverage

Good

Last updated18 Dec 2024

Recent future growth updates

Recent updates

Cigna And The Risk Of PBMs - I'm Staying Out Above $230/Share

Dec 13

These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well

Oct 14
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well

Cigna: This Dividend Grower Could Be Worth Buying Now

Sep 26

Returns On Capital Are Showing Encouraging Signs At Cigna Group (NYSE:CI)

Sep 26
Returns On Capital Are Showing Encouraging Signs At Cigna Group (NYSE:CI)

Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'

Sep 19

The Price Is Right For The Cigna Group (NYSE:CI)

Sep 08
The Price Is Right For The Cigna Group (NYSE:CI)

Cigna Group: Services Focus Leads To Outperformance

Jul 29

Cigna: Game Over For PBMs?

Jul 12

Cigna Group (NYSE:CI) Has A Somewhat Strained Balance Sheet

Jun 14
Cigna Group (NYSE:CI) Has A Somewhat Strained Balance Sheet

Cigna: Will Benefit From Lower Medicaid Enrollments

Jun 11

The Cigna Group (NYSE:CI) Not Lagging Market On Growth Or Pricing

May 27
The Cigna Group (NYSE:CI) Not Lagging Market On Growth Or Pricing

Cigna: An Up-And-Coming Dividend Growth Stock To Buy Now

May 13

Cigna Group's (NYSE:CI) Soft Earnings Don't Show The Whole Picture

May 09
Cigna Group's (NYSE:CI) Soft Earnings Don't Show The Whole Picture

Here's Why We Think The Cigna Group's (NYSE:CI) CEO Compensation Looks Fair for the time being

Apr 18
Here's Why We Think The Cigna Group's (NYSE:CI) CEO Compensation Looks Fair for the time being

Cigna: Time To Sell The Stock After A 50% Return? No, Here's Why

Apr 09

Returns Are Gaining Momentum At Cigna Group (NYSE:CI)

Apr 05
Returns Are Gaining Momentum At Cigna Group (NYSE:CI)

Cigna Continues To Reap Gains From A Shrewd Acquisition Made In 2018

Apr 01

Cigna: Trimming The Fat And Staying Focused

Mar 05

Cigna: Big Buybacks And Total Return Potential

Feb 26

Cigna Group (NYSE:CI) Is Increasing Its Dividend To $1.40

Feb 05
Cigna Group (NYSE:CI) Is Increasing Its Dividend To $1.40

Cigna Q4 Preview: The Analysts' Whisper - Deciphering Cigna's Next Big Leap

Jan 29

We Think Cigna Group (NYSE:CI) Can Stay On Top Of Its Debt

Jan 25
We Think Cigna Group (NYSE:CI) Can Stay On Top Of Its Debt

Why Dividend Growth Investors Should Buy Cigna

Jan 18

It's A Story Of Risk Vs Reward With The Cigna Group (NYSE:CI)

Jan 09
It's A Story Of Risk Vs Reward With The Cigna Group (NYSE:CI)

Cigna Group (NYSE:CI) Is Experiencing Growth In Returns On Capital

Dec 25
Cigna Group (NYSE:CI) Is Experiencing Growth In Returns On Capital

Cigna: Sentiment And Fundamentals On Their Side

Dec 21

Cigna's Merger Fumble: A Festive Financial Rebound

Dec 11

Humana And Cigna Topple On Rumors Of An Unlikely Union

Nov 30

Cigna Delivering Growth At A Great Price

Nov 13

Cigna: Too Cheap To Ignore

Oct 24

Cigna: Buy Rating Driven By Undervaluation & Revenue Growth

Oct 01

Cigna: Seizing Opportunities And Managing Risks In The Healthcare Landscape

Sep 14

Cigna Group: Weaker Than Peers But Still A Buy

Aug 27

Cigna: Buy During The Next Correction (Technical Analysis)

Aug 08

Cigna: Buy While It's Still Cheap And Not Loved

Jun 29

Cigna: Buy This Value Gem Before It Bounces Back

Jun 12

Earnings and Revenue Growth Forecasts

NYSE:CI - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026265,4677,19114,51914,63718
12/31/2025252,0396,92810,56811,19019
12/31/2024244,0353,83311,05711,55616
9/30/2024229,7473,0395,1846,618N/A
6/30/2024216,0083,7087,9609,398N/A
3/31/2024204,1453,62010,16011,625N/A
12/31/2023195,1875,16410,24011,813N/A
9/30/2023189,8665,32810,89212,445N/A
6/30/2023186,0316,67711,41412,902N/A
3/31/2023182,8086,77410,23911,654N/A
12/31/2022180,0316,7047,3618,656N/A
9/30/2022180,0286,6279,57810,832N/A
6/30/2022179,1855,4918,4029,668N/A
3/31/2022176,9865,4016,9288,128N/A
12/31/2021174,2675,3706,0377,191N/A
9/30/2021170,3978,3846,0417,210N/A
6/30/2021167,0288,1514,9155,986N/A
3/31/2021163,1418,4388,4879,556N/A
12/31/2020160,5508,4589,25610,350N/A
9/30/2020157,0095,3007,7648,849N/A
6/30/2020154,6295,2639,33910,415N/A
3/31/2020154,1684,9177,0578,180N/A
12/31/2019153,7435,1048,4359,485N/A
9/30/2019129,6604,2715,8966,818N/A
6/30/2019102,5103,6924,1764,981N/A
3/31/201975,1453,0904,3184,937N/A
12/31/201848,5692,6373,2423,770N/A
9/30/201844,9692,7593,7424,219N/A
6/30/201844,0012,547N/A4,830N/A
3/31/201842,9492,554N/A4,532N/A
12/31/201742,0432,237N/A4,086N/A
9/30/201741,3322,353N/A4,358N/A
6/30/201740,7232,249N/A5,035N/A
3/31/201740,2581,946N/A4,684N/A
12/31/201640,0071,867N/A4,026N/A
9/30/201639,2521,911N/A4,315N/A
6/30/201638,7612,002N/A3,017N/A
3/31/201638,2932,080N/A3,117N/A
12/31/201537,8762,094N/A2,933N/A
9/30/201537,2762,135N/A2,319N/A
6/30/201536,6442,122N/A2,175N/A
3/31/201535,8852,107N/A2,241N/A
12/31/201434,9142,102N/A2,158N/A
9/30/201434,0981,996N/A2,084N/A
6/30/201433,4072,015N/A2,444N/A
3/31/201432,6541,947N/A2,014N/A
12/31/201332,3801,476N/A719N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CI's forecast earnings growth (24.2% per year) is above the savings rate (2.6%).

Earnings vs Market: CI's earnings (24.2% per year) are forecast to grow faster than the US market (15.3% per year).

High Growth Earnings: CI's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CI's revenue (5.6% per year) is forecast to grow slower than the US market (9.1% per year).

High Growth Revenue: CI's revenue (5.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CI's Return on Equity is forecast to be low in 3 years time (19.3%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 22:40
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

The Cigna Group is covered by 48 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullArgus Research Company
Hua HaBaird
Ishan MajumdarBaptista Research